Mannkind Corp

NASDAQ:MNKD   3:59:51 PM EDT
3.96
+0.08 (+1.93%)
Products

FDA Approves Tyvaso Dpi For Treatment Of Pulmonary Arterial Hypertension To Improve Exercise Ability

Published: 05/23/2022 22:15 GMT
Mannkind Corp (MNKD) - FDA Approves Tyvaso Dpi for Treatment of Pulmonary Arterial Hypertension to Improve Exercise Ability.
FDA Says Also Approves Tyvaso Dpi for Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease to Improve Exercise Ability.
Further Company Coverage: Mnkdo ((reuters.
Briefs@thomsonreuters.
Com;)).